Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

November 27, 2018

Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

GenomeWebinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

This One Might Not Be Due to Humans

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Not the Wings

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

More Vaccines on Order

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

Science Studies Include Ion Channel Mutation Prediction Model, Variant Linked to Disrupted Sleep

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

Featured White Papers

AIM-MNP: Implementation of Molecular Profiling in Pediatric Brain Cancer A GenomeWeb eCase Study Transcript

Tackling the Challenges of Serum Proteomics

Categorization of Blood-Based Biomarkers

Stroma Liquid Biopsy: A Pan-Cancer Biomarker Panel of Dysregulation Derived from Blood

Aug

19

Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

24

Featured Webinar

High-Definition Spatial Proteomics to Elucidate the Tumor Immune Microenvironment: A Dana-Farber Case Study

This webinar will discuss how high-definition spatial proteomics, enabled by Multiplexed Ion Beam Imaging (MIBI), can be used to explore the immune microenvironment of tumor biopsy samples, illustrated by a case study at Dana-Farber Cancer Institute.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Menu